# Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

> **NCT03262779** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 20 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** combination nivolumab and ipilimumab

## Key facts

- **NCT ID:** NCT03262779
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03262779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03262779, "Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03262779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*